The PI3K/mTOR/AKT pathway is commonly activated in MCC, and use of the PI3K inhibitor copanlisib, specifically targeting PI3K-α and PI3K-δ isoforms, showed antitumor effects in multiple MCC PDX models compared to other PI3K inhibitors (298). This evidence concerns the gene AKT1 and Merkel cell skin cancer.